<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609332</url>
  </required_header>
  <id_info>
    <org_study_id>OAIC 1164/20</org_study_id>
    <nct_id>NCT04609332</nct_id>
  </id_info>
  <brief_title>Endothelial Damage and Angiogenesis Biomarkers During COVID-19</brief_title>
  <official_title>Association of Endothelial Damage and Angiogenesis Biomarkers With Morbidity and Mortality in SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure.&#xD;
      Autopsies from these patients show severe endothelial damage with extensive vascular&#xD;
      thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of&#xD;
      new vessel growth through intussusceptive angiogenesis.&#xD;
&#xD;
      This research aims to study endothelial damage and angiogenesis biomarkers and its&#xD;
      association with major cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study the presence of endothelial damage and angiogenic biomarkers with major&#xD;
      cardiovascular events, the investigators will perform an observational study to evaluate&#xD;
      plasma biomarkers concentrations in Covid-19 patients hospitalized in critical care units.&#xD;
&#xD;
      After ethical review board approval, the investigators will select 40 patients admitted to&#xD;
      intensive care units (ICU). After patient written consent or if the participants are unable&#xD;
      to consent, after a relative subrogated acceptance, the investigators will collect blood&#xD;
      samples in the first 24 hrs and on the 10th day of hospitalization.&#xD;
&#xD;
      Venous blood samples are collected. After obtaining all samples, serum Syndecan-1,&#xD;
      thrombomodulin, ANG-2, FGF basic, HGF, IL-8, PDGF-BB, TIMP-1, TIMP-2, TNFα y VEGF will be&#xD;
      determined by a researcher blinded to the patient using commercially available Elisa kits.&#xD;
      The concentration of each biomarker at each sample time will be compared. The investigators&#xD;
      will observe clinical outcomes after one, 3, 6, and 12 months after the hospitalization.&#xD;
&#xD;
      The investigators found no previous data of this measurement in the COVID-19 scenario. In&#xD;
      this observational study, the investigators select a sample size on convenience for the&#xD;
      primary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Change from Baseline Syndecan-1 concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma Syndecan-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline ANG-2 concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma ANG-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline FGF basic concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma FGF basic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline HGF concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma HGF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline IL-8 concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma IL-8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline PDGF-BB concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma PDGF-BB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline TIMP-1 concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma TIMP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline TIMP-2 concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma TIMP-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline TNFα concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma TNFα</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline VEGF concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma VEGF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Thrombomodulin concentration at 10th day</measure>
    <time_frame>24 Hours, 10 Days</time_frame>
    <description>Elevation of plasma Thrombomodulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>1 month, 3 months, 6 months 12 months.</time_frame>
    <description>Acute coronary syndrome, myocardial injury, pulmonary embolism, and death.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <condition>Angiogenesis</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Cardiovascular Morbidity</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Endothelial damage and angiogenic biomarkers</intervention_name>
    <description>Blood samples for biomarkers study</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will include Covid 19 patients admitted to ICU with the need for oxygen&#xD;
        and ventilatory support. Blood plasma biomarkers will be obtained on the first and 10th day&#xD;
        of hospitalization. Information on major cardiac events will be obtained from the patient&#xD;
        clinical file and by phone interview after hospitalization.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients older than 18 years&#xD;
&#xD;
          2. Patient with a diagnosis of COVID-19 confirmed by PCR&#xD;
&#xD;
          3. Patient with radiological image suggestive of COVID-19 with pending confirmation&#xD;
&#xD;
          4. Need for ventilatory support with oxygen therapy by HFNC (High-flow nasal cannula)&#xD;
&#xD;
          5. Need for invasive mechanical ventilation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with an image suggestive of COVID-19 with negative PCR&#xD;
&#xD;
          2. Anticoagulation users before admission for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Felipe Maldonado, M.D., M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico de la Universidad de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Felipe Maldonado, M.D., M.Sc.</last_name>
    <phone>+56 2 2978 8221</phone>
    <email>fmaldonado@uchile.cl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico de la Universidad de Chile</name>
      <address>
        <city>Independencia</city>
        <state>Santiago</state>
        <zip>8380456</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Maldonado, M.D., M.Sc.</last_name>
    </contact>
    <investigator>
      <last_name>Mónica Cáceres, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oscar Cerda, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Romero, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Valls, M.D., M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catalina Valdes, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chile</investigator_affiliation>
    <investigator_full_name>Felipe Andrés Maldonado Caniulao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Syndecan-1</keyword>
  <keyword>Thrombomodulin</keyword>
  <keyword>VEFG</keyword>
  <keyword>ANG-2</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

